A Drug Combination Rescues Frataxin-Dependent Neural and Cardiac Pathophysiology in FA Models

A Drug Combination Rescues Frataxin-Dependent Neural and Cardiac Pathophysiology in FA Models

Friedreich’s ataxia (FA) is an inherited multisystemic neuro- and cardio-degenerative disorder. Seventy-four clinical trials are listed for FA (including past and present), but none are considered FDA/EMA-approved therapy. To date, FA therapeutic strategies have focused along two main lines using a...

Full description

Bibliographic Details
Main Authors: Rosella Abeti, Mittal Jasoliya, Sahar Al-Mahdawi, Mark Pook, Cristina Gonzalez-Robles, Chun Kiu Hui, Gino Cortopassi, Paola Giunti
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-05-01
Series:Frontiers in Molecular Biosciences
Subjects:
Friedreich’s Ataxia (FA)
Frataxin (FXN)
Dimethyl fumarate (DMF)
Resveratrol (Resv)
Mitochondrial membrane potential (ΔΨm)
Reactive Oxygen species (ROS)
Online Access:https://www.frontiersin.org/articles/10.3389/fmolb.2022.830650/full

Internet

https://www.frontiersin.org/articles/10.3389/fmolb.2022.830650/full

Similar Items